WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Stock

$400.23+2.65 (+0.67%)
Updated Apr 11, 2024
VRTX Price
$400.23
Fair Value Price
$400.23
Market Cap
$103.38B
52 Week Low
$316.43
52 Week High
$448.40
P/E
28.49x
P/B
5.88x
P/S
10.63x
PEG
11.61x
Dividend Yield
N/A
Revenue
$9.87B
Earnings
$3.62B
Gross Margin
87.2%
Operating Margin
44.83%
Profit Margin
36.7%
Debt to Equity
0.29
Operating Cash Flow
$4B
Beta
0.74
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VRTX Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VRTX ($400.23) is overvalued by 0% relative to our estimate of its Fair Value price of $400.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VRTX ($400.23) is not significantly undervalued (0%) relative to our estimate of its Fair Value price of $400.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VRTX ($400.23) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VRTX due diligence checks available for Premium users.

Be the first to know about important VRTX news, forecast changes, insider trades & much more!

VRTX News

Valuation

VRTX fair value

Fair Value of VRTX stock based on Discounted Cash Flow (DCF)
Price
$400.23
Fair Value
$400.23
Overvalued by
0.00%
VRTX ($400.23) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VRTX ($400.23) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VRTX ($400.23) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VRTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
28.49x
Industry
14.34x
Market
43.63x
VRTX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
VRTX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

VRTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.88x
Industry
6.04x
VRTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VRTX price to earnings growth (PEG)

For valuing profitable companies with growth potential
VRTX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

VRTX's financial health

Profit margin

Revenue
$2.5B
Net Income
$968.8M
Profit Margin
38.5%
VRTX's Earnings (EBIT) of $4.42B... subscribe to Premium to read more.
Interest Coverage Financials
VRTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$22.7B
Liabilities
$5.1B
Debt to equity
0.29
VRTX's short-term assets ($14.14B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VRTX's short-term assets ($14.14B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VRTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$234.6M
Investing
-$886.5M
Financing
-$119.8M
VRTX's operating cash flow ($3.54B)... subscribe to Premium to read more.
Debt Coverage Financials

VRTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VRTX$103.38B+0.67%28.49x5.88x
REGN$101.02B-1.70%24.84x3.89x
MRNA$40.89B-0.12%-8.68x2.95x
ARGX$22.47B-0.82%-67.69x5.05x
BNTX$20.68B-1.85%20.68x0.94x

Vertex Pharmaceuticals Stock FAQ

What is Vertex Pharmaceuticals's quote symbol?

(NASDAQ: VRTX) Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol VRTX. Vertex Pharmaceuticals stock quotes can also be displayed as NASDAQ: VRTX.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

What is the 52 week high and low for Vertex Pharmaceuticals (NASDAQ: VRTX)?

(NASDAQ: VRTX) Vertex Pharmaceuticals's 52-week high was $448.40, and its 52-week low was $316.43. It is currently -10.74% from its 52-week high and 26.48% from its 52-week low.

How much is Vertex Pharmaceuticals stock worth today?

(NASDAQ: VRTX) Vertex Pharmaceuticals currently has 258,307,816 outstanding shares. With Vertex Pharmaceuticals stock trading at $400.23 per share, the total value of Vertex Pharmaceuticals stock (market capitalization) is $103.38B.

Vertex Pharmaceuticals stock was originally listed at a price of $16.50 in Dec 31, 1997. If you had invested in Vertex Pharmaceuticals stock at $16.50, your return over the last 26 years would have been 2,325.64%, for an annualized return of 13.05% (not including any dividends or dividend reinvestments).

How much is Vertex Pharmaceuticals's stock price per share?

(NASDAQ: VRTX) Vertex Pharmaceuticals stock price per share is $400.23 today (as of Apr 11, 2024).

What is Vertex Pharmaceuticals's Market Cap?

(NASDAQ: VRTX) Vertex Pharmaceuticals's market cap is $103.38B, as of Apr 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vertex Pharmaceuticals's market cap is calculated by multiplying VRTX's current stock price of $400.23 by VRTX's total outstanding shares of 258,307,816.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.